Logo

NIH Targeted Delivery Interest Group Seminar Series - Shared screen with speaker view
Husain
01:01:50
Thank you for emphasizing the FDA's point of view of SOC treatment as a control arm.
Moudgil Kamal
01:04:17
some papers describe nanomedicine as that with particles that are less than 100nm (nanoparticles). So it seems that is too restrictive and technical definition of nanomedicine.
1.Kien Nguyen, NIAID
01:15:03
why cancer samples from different patients responded differently to drugs?
Alison Director-Myska
01:17:53
Targeting as you presented it is important for us in Chem / Bio Defense, too. As is the comment about comparing to standard of care.
Sharad Verma
01:22:06
@Kien - differences in intratumoral distribution and cancer cell heterogeneity are among key factors
1.Kien Nguyen, NIAID
01:32:20
Thanks Prof Park for the interesting seminar!
Mindy Davis, NIAID, NIH
01:33:17
Great kickoff to this new series.